OSCEOLA, WI and MOUNTAIN VIEW, CA – Surpass, Inc. (“Surpass”), a recognized leader in translational preclinical research, today announced that it has established a Surpass Innovation Award to support University of California, San Francisco’s (UCSF’s) leading researchers working on early-stage medtech innovation within the Clinical and Translational Science Institute (CTSI).
As a trusted partner for companies developing new medical technologies, Surpass understands the challenges entrepreneurs face in securing capital early in the medical innovation cycle. Raising capital during this initial phase can be difficult. Many promising technologies fail to attract early-stage funding to generate the necessary preclinical data to win potential investors for moving these technologies forward. For this reason, Surpass has established the Surpass Innovation Award, to provide medical entrepreneurs the support and resources needed to obtain their first preclinical data. “We are partnering with Centers of Biomedical Excellence and their entrepreneurs to support the future of medical innovation. Surpass is committed to being an active member of the Biomedical Community and a champion for the medical innovation continuum,” said Dr. Tim Pelura, President and CEO of Surpass. “UCSF and Surpass have come together to form a unique partnership, one where public academia and private industry work together for the greater good to ensure critical life-saving and life-improving products continue to advance into the hands of physicians and patients.”
This marks an important industry partnership for the Medical Devices track of CTSI’s Catalyst Awards program, which focuses specifically on discovery and development of novel clinically and commercially viable medical device tools and products. June Lee, MD, FACCP, director of CTSI’s Early Translational Research program, which manages the Catalyst Awards, echoed that sentiment. “This collaboration marks an important step in cultivating critical industry-academic partnerships in our Medical Device Track. It represents a novel partnership with industry that further supports the broader mandate of UCSF and the NIH Clinical and Translational Science Awards, to accelerate research to improve health.”
The Surpass Innovation Award will provide UCSF CTSI Program Awardees their first preclinical proof-ofconcept data. Surpass will support the Awardees through the entire preclinical study process, and provide assistance during the due diligence phase with investors to help optimize the chances of moving these lifesaving technologies forward to the patients who need them.
About Surpass
At Surpass, our innovative approach to preclinical research goes beyond the ordinary. We’re changing the rules for a better way to get from concept to reality.
Surpass is a trusted, preclinical contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.
Surpass’ breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and much more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (715) 294-4371 (Greater Twin Cities) or (650) 938-3675 (Silicon Valley).
Visit www.surpassinc.com for more information. Connect with Surpass, Inc. on, LinkedIn, YouTube, Twitter, Facebook, and Google+
About the Catalyst Awards Program
The Catalyst Awards Program solicits applications from UCSF investigators with compelling translational research findings who wish to move beyond the research bench and into product development; it includes four different tracks of focus, therapeutics, diagnostics, devices and digital health. The Catalyst Awards process includes a review of applications by a panel of more than 180 expert advisors who have specialized experience related to product development and commercialization.
About UCSF
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy, a graduate division with nationally renowned programs in basic biomedical, translational and population sciences, a preeminent biomedical research enterprise and two top-tier hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospital. Please visit www.ucsf.edu.
UCSF is home to the Clinical and Translational Science Institute, a campus-wide institute that provides infrastructure, services and training to accelerate and support clinical and translational research. UCSF’s CTSI is part of the 60-institution Clinical and Translational Science Awards (CTSA) consortium funded by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health’s (NIH). The CTSA aims to strengthen and support the entire spectrum of translational research from scientific discovery to improved patient care.
